in Stockholm. Of these, 6 non-Jewish patients (2 women and 4 men) with sporadic GD1 who initially underwent diagnostic ASP and TB as part of the evaluation for cytopenia accompanied by splenomegaly were included in this analysis.
Bone marrow samples were collected under local anesthesia from an entry site on the posterior iliac crest of patients in the prone position. The samples were stained with May-Grünwald-Giemsa (BM-S) or hematoxylin and eosin (BM-TB) stains according to routine methods. Stored bone marrow samples were reassessed by a hematopathologist for study purposes.
Differential counts of BM-S were made under ×400 magnification using an Olympus BX 40 microscope. Samples from each patient consisted of 2 slides. On each slide, 500 nucleated cells were counted and then averaged. An assessment of the composition of BM-TB, ie, a relative proportion of the hematopoietic tissue, Gaucher cells, fat tissue, and trabecular bone, was carried out using digital images and the GNU Image Manipulation Program (GIMP2) (freeware available at www.gimp.org).
tissues rich in cells of the mononuclear phagocyte system, such as the spleen, liver, and, in particular, the bone marrow.
The results of ASP and/or TB examinations often give the first clue towards GD diagnosis in non--Jewish patients who do not have any previously known GD1-affected family members (ie, sporadic GD1), since they disclose the presence of macrophages having a Gaucher cell appearance.
2,4,5
However, because there are virtually no published studies comparing ASP and TB in the diagnostic workup of GD, little is known about the utility of these 2 methods in the assessment of bone marrow involvement in GD.
The aim of our study was to compare the results of cytological and histological analyses of BM-S and BM-TB, obtained by means of ASP and TB, in adult non-Jewish patients with newly diagnosed GD1.
PATIENTS ANd METHOdS
There are currently 35 patients diagnosed with GD1 in Sweden.
7 Between 2002 and 2013, 16 adults with GD1 were followed at the Karolinska University Hospital The reference values for cytological and histological composition of bone marrow samples in healthy individuals were obtained from the studies of Burkhardt et al. 8 and Sundström and Öst. 9 The nonparametric Wilcoxon signed-rank test was used to evaluate statistically significant differences between the results of ASP and TB examinations for the detection of Gaucher cells (the relatively small sample analyzed could not be assumed to be normally distributed). The P value was 2-tailed and calculated using Stata 9.2 (StataCorp LP, College Station, TX, USA). A P value of less than 0.05 was considered statistically significant.
The study protocol was developed according to the ethical standards of the Declaration of Helsinki and approved by the local ethics committee in Stockholm. All patients provided their informed consent to participate in the study.
RESuLTS
The median age of the patients was 65 years (range, 21-84 years). Three patients (50%) had undergone splenectomy. All but 1 patient (83%) carried at least 1 N370S allele with the c.1226A>G mutation in the GBA1 gene. Patient characteristics are presented in TABLE 1.
Examples of cytological and histological images of bone marrow samples, obtained by ASP and TB from one of the patients, are shown in the FIGuRE.
The results of cytological analyses of BM-S including identified Gaucher cells are presented in TABLE 2. The median number of Gaucher cells identified in the studied patients was 4 (range 1-18), and the median percentage of Gaucher cells among all nucleated bone marrow cells was 0.4% (range, 0.1%-1.8%).
The proportions of hematopoietic tissue, Gaucher cells, fat tissue, and trabecular bone in BM-TB from the patients are presented in TABLES 3 and 4. The Gaucher cell burden in BM-TB ranged from 22% to 36% (median value, 28%) and the ratio of Gaucher cells to hematopoietic tissue ranged from 34% to 54% (median value, 47%). The ratio of Gaucher cells to hematopoietic tissue in ASP Digital imaging of BM-S and BM-TB was carried out using the Nikon DX m 1200F digital camera mounted on the Nikon Eclipse E1000 microscope with a ×40 objective for the BM-S and ×2 respective ×20 objectives for the BM-TB.
In all patients, the diagnosis of GD was confirmed by low glucocerebrosidase activity in peripheral blood leukocytes. All patients also demonstrated increased plasma chitotriosidase activity (TABLE 1). The activity of both enzymes was assessed by a reference laboratory according to standard practice.
5,7 Next, direct DNA sequencing performed at the Academic Medical Center in Amsterdam, Netherlands, revealed mutations in the GBA1 gene in all cases. The patients' medical records were reviewed to collect relevant clinical data. 1  260  5  9  94  313  12  2  25  279  0  0  1  1000   2  335  15  22  53  428  7  3  71  62  1  0  3  1000   3  154  10  8  35  469  21  11  71  214  0  1  6  1000   4  259  9  17  124  401  32  1  28  114  0  0  15  1000   5  173  8  12  7  560  7  4  62  124  40  0  3  1000   6  355  8  22  71  300  12  0  83  121  10  0 other diseases, including malignancies, chronic inflammatory disorders, and AIDS. These patients have normal ability to catabolize glucocerebroside but rapid cell turnover causes functional overload of the hydrolyzing enzyme, which leads to formation of pseudo-Gaucher cells.
The absence of Gaucher cells in bone marrow specimens obtained by means of ASP from GD1 patients diagnosed by enzymatic assays has also been reported. 20 However, this finding was not studied further owing to changed diagnostic practices for GD among Jewish patients, which shifted towards the enzymatic and genetic methods. Currently, if GD is suspected based on morphological findings, such as the presence of Gaucher cells in tissue specimens, the gold standard diagnosis requires confirmation by appropriate enzymatic and genetic assays. [1] [2] [3] [4] [5] 15 The choice of the bone marrow examination method is often random, influenced by many different factors related both to the patient (eg, concomitant symptoms, comorbidities, local conditions at the examination site, etc) and the physician (eg, local routines, personal experience, etc). TB has been introduced into routine hematological diagnostic workup relatively recently in many countries (approximately the last 20 years), at the time when bone marrow examination was no longer recommended for the sole purpose of GD diagnosis. 21 The results of the present study indicate a low sensitivity of ASP in detecting Gaucher cells in the bone marrow. Most analyzed patients (4 of 6) had 6 or fewer Gaucher cells among 1000 counted nucleated hematopoietic cells. Of note, routine differential count in BM-S usually includes only 200 nucleated hematopoietic cells. Thus, there is a serious risk of overlooking GD in some patients when using only ASP, and we conclude that ASP is not a reliable diagnostic tool for GD1.
Gaucher cells are often tightly packed in the affected areas of the bone marrow tissue and therefore difficult to aspirate by ASP, which may explain our findings. Additional problems with aspiration of Gaucher cells can result from increased density of reticulin fibers in the bone marrow. The sensitivity of TB for detection of Gaucher cells in the bone marrow is much higher, and the observed detected Gaucher cell burden in the present study was approximately 100-fold higher compared with cytological specimens obtained by ASP. Although histological findings are reliable in the diagnosis of GD1, TB is a more advanced procedure than ASP, and it should be performed by an experienced physician.
When an ASP sample is negative for Gaucher cells (false-negative ASP result) and an enzyme assay for GD is not performed, there is a serious threat that the diagnosis of GD1 may be postponed for many years.
16 Therefore, proper interpretation and recognition of the limitations of ASP results are crucial in avoiding diagnostic delays in patients affected with this treatable condition.
was strikingly lower than that in TB samples. Similar results were observed in all patients studied and the difference between the 2 diagnostic modalities in the whole group was statistically significant (Wilcoxon signed-rank test: P = 0.028).
dISCuSSION The diagnosis of inherited metabolic disorders, including GD, may be difficult and prolonged. Thrombocytopenia, anemia, splenomegaly, hepatomegaly, and bone manifestations are the most typical signs of the most prevalent form of GD, GD1. [1] [2] [3] [4] [5] 10 The presence of central nervous system disease, in addition to the above symptoms, is a hallmark of GD type 2 and type 3. 11 GD is well known for its striking phenotypic diversity, which can complicate diagnosis. 10-13 Although according to the European Union definition, GD belongs to so called rare diseases (ie, affecting less than 1 persons/2000 inhabitants), 14 the diagnosis of GD1 should be considered in any patient who presents with a long clinical history of splenomegaly and thrombocytopenia, in children with acute or chronic bone pain, growth retardation, and in individuals with nontraumatic avascular necrosis of a large joint at any age. 1, 10 In patients of Ashkenazi Jewish ancestry, the frequency of GD is 1 in 800, while hematologic malignancies are much less frequent (1 in 2500 people).
15 Owing to such a high prevalence of GD among Jewish patients, enzyme assays (ie, glucocerebrosidase activity in peripheral blood leukocytes as well as plasma chitotriosidase activity and/or CCL18/PARC concentration) aimed at GD diagnosis should precede bone marrow examination, unless there is a strong reason to suspect another cause of splenomegaly and thrombocytopenia. 1, 2, 15 In the non-Ashkenazi populations, GD is markedly less frequent (1 in 40,000-200,000 people) than hematologic malignancies. 1 In milder forms of GD1, when the clinical picture is scant, and in the absence of any known affected family member, GD remains a diagnostic challenge. It is often not included in the differential diagnosis of thrombocytopenia even by experienced hematologists. 16 However, sooner or later, the presence of the most frequent initial GD1 symptoms, splenomegaly and/or thrombocytopenia, leads to hematological diagnostic workup. 4, 5, 17, 18 In such cases, routine diagnostic procedures include ASP for the cytological assessment of BM-S and TB for the histological evaluation of BM-TB. In many non-Jewish patients with sporadic GD1, the results of bone marrow examinations provide the first clue to diagnosis.
Historically, the diagnosis of GD was usually based on a morphological examination of bone marrow specimens, liver biopsy, or a surgically removed spleen.
5,15 Until 1966, when pseudo--Gaucher cells had been described for the first time in chronic myeloid leukemia, it was believed that the presence of Gaucher cells in the bone marrow was pathognomonic of GD.
19 Later, pseudo-Gaucher cells were also reported in many
